Mounjaro 'golden dose' revealed to stop 'food noise'
Patient dosage, starting body mass index (BMI) and percentage of body weight lost were reviewed, to provide people exploring treatment a realistic snapshot of what to expect and show what real success looks like.
Mounjaro users report surprising side effect - pharmacists share their tips https://t.co/9tXoCc5gCk https://t.co/KGLZUpUbcL — Telegraph & Argus (@Bradford_TandA) August 5, 2025
Leading online pharmaceutical company Oxford Online Pharmacy has conducted a study of 100 anonymised patients prescribed once-weekly Mounjaro (tirzepatide) injections.
The data aims to counteract unhealthy beliefs that hunger equals failure, which may lead to unnecessary concerns and calls for increased doses. The analysis revealed that patients in the analysis lost up to 39kg, with consistent results across a range of doses.
Kiran Jones, Clinical Pharmacist at Oxford Online Pharmacy, says: 'This study reinforces that healthy, sustainable weight loss is possible without excessive pressure or maximal dosing.
'People think these medicines switch off hunger completely, but that's not how they work. Being able to eat is normal. Success looks different for everyone, and often, the biggest wins are quiet ones: more energy, less breathlessness, and better sleep.
'Becoming healthier without extreme diets or private clinics is a powerful example of what good, regulated care can achieve. Patients need safety, not pressure.'
All patients started on the recommended dose of 2.5mg, which gradually increased depending on individual response (up to 12.5mg), with 86% maintaining a moderate dose of 10mg or lower. The most common dose for over half of the patients was 5mg.
It varies for everyone, but I did 6 months of Mounjaro and "I feel absolutely starving when I don't eat enough" was 100% gone. However, dosing is poorly managed. They wanted to increase all the time and that made me sick, so I stayed on the lowest dose and it worked great. — Peter Cooper (@cooperx86) August 5, 2025
Weight loss generally increased with dose, but the data shows this does not follow a strictly linear pattern. Patients on 7.5mg showed the highest average weight loss overall, showing smaller doses can be effective, and making this the 'golden dose' for many people.
Similarly, higher BMI correlated with greater weight loss, but not in all patients.
The study also highlights the importance of celebrating non-weight loss wins, discussing how the right dose helps users strike a balance between appetite control, tolerability and overall wellbeing.
However, the experts say that they should not switch off hunger entirely - it just helps regulate appetite and increase feelings of satisfaction. Being able to enjoy food can be a sign that the medicine is working appropriately.
Meanwhile, before experiencing weight loss, patients reported improvements, including better sleep, more stable energy and mood, reduced cravings, and increased motivation to move.
What is 'food noise'?
'Food noise' is thinking about food even when you aren't physically in need of food. Experts say it is a psychologically driven process, unlike real hunger, which comes from your body needing nutrients and fuel.
GP registrar Dr Jack Mosley – whose dad was BBC presenter Dr Michael Mosley - has written a book titled Food Noise.
Recommended reading:
"There's multiple reasons we eat," he says. "One of the big drivers is simply appetite, and that's centrally controlled in our brain and through our guts.
"But our cravings – that internal food monologue, which I refer to as the 'food noise' – that can be turned up if you are hungry, but plenty of people, eat even when they're not hungry.
"Many of us can relate to it, when we're stressed, we're not typically eating nutritious foods. We want that easy, accessible junk food. So we want the sugary, salty snacks. We want that sugar high. The weight-loss drugs can reduce our appetite and our cravings, but they're not necessarily going to address things like our emotional hunger."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
an hour ago
- Daily Mirror
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.
Sky News
4 hours ago
- Sky News
Mounjaro manufacturer to hike UK price of weight loss drug by up to 170%
The UK cost of weight loss drug Mounjaro will increase by up to 170%, its US manufacturer has said, as the White House pushes for a price hike abroad so costs can be cut for Americans. The new price, announced by manufacturer Eli Lilly on Thursday, also applies to Lilly's type 2 diabetes medicine that has the same name. The price for a month's supply of the highest dose of the medicine will increase from £122 to £330, Lilly said, adding the adjustment will be made next month. The higher price will not affect those prescribed the medicine through the NHS, which has a separate deal, a Lilly spokesperson said. The US drugmaker said that when it launched Mounjaro in the UK it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through the NHS. "We are now aligning the list price more consistently," Lilly said. Lilly did not say what price it has agreed with the NHS, but said it was working with private UK healthcare providers who can set their own prices, such as online pharmacies, to ensure the medicines remain available. It follows Sky News earlier this month revealing only eight of 42 NHS Integrated Care Boards in England were providing the weight loss treatment to patients, and many of the rest were unable to guarantee when it would be available. 2:32 Lilly's decision comes as US President Donald Trump is pushing for lower domestic prices while encouraging price hikes overseas. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Mr Trump says he wants to narrow this gap to stop Americans from being "ripped off". The company issued a statement online saying: "Lilly supports the administration's goal of keeping the United States the world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries. "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US."
The Guardian
6 hours ago
- The Guardian
Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands
The price of the weight loss jab Mounjaro will rise by up to 170% in the UK, its US manufacturer has said, as Donald Trump ramps up pressure on drugmakers to increase their prices for Europeans so that they can make them more affordable for Americans. Eli Lilly has said it will increase the price of the drug from September, with a month's supply of the highest dose rising from £122 to £330. Mounjaro contains tirzepatide and is self-administered in once-a-week injections. When it launched in Britain in February 2024, Eli Lilly agreed to a list price 'significantly below' its other European markets to stop delays in availability of the medicine through the NHS. The increase in the list price will align it 'more consistently', the company said, although it added the NHS would not pay the new higher price to ensure continued access for the people with obesity and type 2 diabetes receiving it through the health service. Eli Lilly said it was working with private healthcare providers, which could negotiate their own confidential discounts with the company. Trump has threatened to use 'every tool in our arsenal' to crack down on pharmaceutical companies charging higher prices in the US compared with other nations. The US pays about three times more for drugs compared with other developed countries, according to the Rand Corporation thinktank. On 31 July, Trump sent letters to 17 of the world's biggest drugmakers, including Eli Lilly and Novo Nordisk, demanding cuts to drug prices for Americans within 60 days. 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government and American patients,' Trump wrote. 'But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices. 'Americans are demanding lower drug prices, and they need them today.' In May, Trump told reporters that a friend in London had told him he had bought the 'fat shot drug' for $88, compared with $1,300 in New York. Pharmaceutical companies have cashed in on huge demand for weight loss treatments. Denmark's Novo Nordisk has become one of the most prominent names in the field, launching Wegovy in the UK in September 2023, turning it into one of the most valuable companies in Europe. While the jabs have increased profits at big pharmaceutical companies, they are racing to develop an equivalent pill, which would be a more convenient and cheaper alternative for patients and healthcare authorities. Eli Lilly said this month that a pill in early trial stages showed that participants on their highest dose lost an average of 12.4% of their body weight, compared with 0.9% of the control group. Novo Nordisk has submitted its oral weight loss drug for approval in the US. Its trial results showed that participants could lose about 15% of their body weight.
